期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

小剂量利妥昔单抗治疗继发于结缔组织病的血小板减少症七例临床研究 被引量：3

原文传递
导出
摘要 目前，继发于结缔组织病（CTD）的血小板减少症被归入继发性免疫性血小板减少症（sITP）的范畴。相对于原发免疫性血小板减少症（ITP），继发于结缔组织病的免疫性血小板减少症（CTD—sITP）发病机制更为复杂，但两者的发病机制也存在一些共性，例如都存在血小板糖蛋白抗体以及T、B淋巴细胞的免疫耐受损伤心。
作者 王宏梅 杨艳辉 宣旻 薛峰 刘晓帆 刘永泽 张磊 杨仁池
机构地区 中国医学科学院、北京协和医学院血液学研究所、血液病医院
出处 《中华血液学杂志》 CAS CSCD 北大核心 2012年第9期763-765,共3页 Chinese Journal of Hematology
基金 国家自然科学基金（81070397） 卫生公益行业科研专项经费项目（201202017） 国家科技重大专项基金（2011ZX09302-007-04） 天津市应用基础及前沿技术研究计划重点项目（10JCZDJC19700）
关键词 免疫性血小板减少症 结缔组织病 继发性 临床研究 单抗治疗 利妥昔 小剂量 发病机制
分类号 R593.2 [医药卫生—内科学]
  • 相关文献

参考文献15

  • 1Rodeghiem F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombo- cytopenic purpura of adults and children: report from an interna- tional working group. Blood, 2009, 113:2386-2393.
  • 2Cines DB, Liebman H, Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin He matol, 2009, 46 :S2-14.
  • 3Jacob N, Guo S, Mathian A, et al. B Cell and BAFF dependence of IFN-alpha-exaggerated disease in systemic lupus erythematosus- prone NZM 2328 mice. J Immunol, 2011, 186:4984-4993.
  • 4Zhou Z, Yang R. Rituximab treatment for chronic refractory idio- pathic thrombocytopenic purpura. Crit Rev Oneol Hematol, 2008, 65:21-31.
  • 5Lehembre S, Macario-Barrel A, Musette P, et al. Rituximab treat- ment for immune thrombocytopenia associated with systemic lupuserythematosus. Ann Dermatol Venereol, 2006, 133:53-55.
  • 6隋涛,薛峰,赵海丰,葛菁,周虎,张磊,白洁,杨仁池.小剂量利妥昔单抗治疗慢性特发性血小板减少性紫癜疗效分析[J].中华血液学杂志,2010,31(3):161-163. 被引量：42
  • 7隋涛,张磊,周泽平,薛峰,葛菁,杨仁池.两种小剂量利妥昔单抗治疗方案治疗原发免疫性血小板减少症疗效比较[J].中华血液学杂志,2011,32(9):583-586. 被引量：21
  • 8Zheng WJ, Zhang X, Wang Q, et al. Refractory severe connective tissue disease thrombocytopenia: is rituximab treatment effective and safe? Ann Rheum Dis, 2009, 68:1077-1078.
  • 9顾越英.风湿性疾病//王吉耀.内科学.1版.北京:人民卫生出版社,2005:1041-1051.
  • 10Nossent JC, Swaak AJ. Prevalence and significance of haemato- logical abnormalities in patients with systemic lupus erythemato- sus. Q J Med, 1991, 80:605-612.

二级参考文献22

  • 1邹农,华宝来,王书杰,朱铁楠,赵永强.利妥昔单抗治疗难治性特发性血小板减少性紫癜一例[J].中华医学杂志,2005,85(6):432-432. 被引量：4
  • 2中华医学会血液学学会血栓与止血学组.几种出血性疾病诊断（及疗效）标准的修订[J].中华血液学杂志,1995,16:331-331.
  • 3Portielje JE,Westendorp RG,Kluin-Nelemans HC.Morbidity and mortality in adults with idiopathic thrombocytopenic purpura.Blood,2001,97:2549-2554.
  • 4Yang R,Han ZC.Pathogenesis and management of chronic idiopathic thrombocytopenie pttrpura:an update.Int J Hematol.2000,71:18-24.
  • 5Godeou B,PorcherR,Fain O,et al.Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura:results of a prospective muhicenter phase 2 study.Blood,2008,112:999-1004.
  • 6Zhou z,Yang R.Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura.Crit Rev Oncol Hematol,2008,65:21-31.
  • 7Rodeghiero F,Stasi R,Gemsheimer T,et al.Standardization of terminology,definitions and outcome criteria in immune thrombocytopenic purpura of adults and children:report from an intcmational working group.Blood,2009,113:2386-2393.
  • 8Zaja F,Battista ML,Pirrona MT,et al.Lower dose rituximab is active in adults patients with idiopathic thrnmbocytopenic purpura.Haematologica,2008,93:930-933.
  • 9Arnold DM,Dentali F,Crowther MA,et al.Systematic review:efficacy and safely of rituximab foradults with idiopathic thrombocytopenic purpura.Ann Intern Med,2007,146:25-33.
  • 10Stasi R,Cooper N,Del Poela G,et al.Analysis of regulatory Tcell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab.Blood,2008,112:1147-1150.

共引文献56

同被引文献26

  • 1张之南,郝玉书,赵永强,等.血液病学.2版.北京:人民卫生出版社,2011.1350-1352.
  • 2Jung Y, Ahn H, Kim DS, et al. Improvement of biological andpharmacokinetic features of human interleukin-11 by site-directed mutagenesis. Biochem Biophys Res Commun, 2011,405 (3) : 399- 404.
  • 3Ragni MV, Jankowitz RC, Jaworski K, et al. Phase 11 prospective open-label trial of recombinant interleukin-11 in women with mild yon Willebrand disease and refractory menorrhagia. Thromb Haemost, 2011,106(4) :641-645.
  • 4Wu S, Zhang Y, Xu L, et al. Multicenter, randomized study of genetically modified recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in cancer patients receiving chemotherapy. Support Care Cancer, 2012,20( 8 ) : 1875- 1884.
  • 5Jung Y,Ahn H,Kim D S,et al.Improvement of biological and pharmacokinetic features of human interleukin-11 by site-directed mutagenesis[J].Biochem Biophys Res Commun,2011,405(3):399-404.
  • 6Ragni M V,Jankowitz R C,Jaworski K,et al.Phase II prospective open-label trial of recombinant interleukin-11 in women with mild von Willebrand disease and refractory menorrhagia[J].Thromb Haemost,2011,106(4):641-645.
  • 7Wu S,Zhang Y,Xu L,et al.Multicenter,randomized study of genetically modified recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in cancer patients receiving chemotherapy[J].Support Care Cancer,2012,20(8):1875-1884.
  • 8Lammering,J.C.,Wang,D.S.,Shin,L.K.et al.Heparin-induced thrombocytopenia(HIT)causing portosplenic,superior mesenteric,and splenic vein thrombosis resulting in splenic rupture and pulmonary emboli formation[J].Clinical imaging,2012,36(6):865-868.
  • 9Hron,G.,Knutson,F.,Thiele,T.et al.Alternative diagnosis to heparin-induced thrombocytopenia in two critically ill patients despite a positive PF4/heparin-antibody test[J].Upsala journal of medical sciences,2013,118(4):279-284.
  • 10薛胜利,戴兰,陈艳,邱桥成,陈苏宁,孙爱宁,吴德沛.G-CSF对急性淋巴细胞白血病细胞增殖活性的影响及协同化疗药物杀伤作用的实验研究[J].中华血液学杂志,2011,32(1):61-63. 被引量：8

二级引证文献7

中华血液学杂志
2012年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部